Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYS006 in moderate to severe inflammatory acne
NL-OMON50746Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LYS006 in acne vulgaris and inflammatory acne (3 arms), sponsored by Novartis. Primary endpoint: Baseline-adjusted total inflammatory facial lesion count at Week 12. Started Sep 2018; status: active, not recruiting.
02
Drugs
LYS006
03
Conditions
acne vulgarisinflammatory acne
Beyond the preview
Go deeper on NL-OMON50746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50746.